Evidence map›Paper›PMID 39238030›Full record

ArticleMolecular neurodegeneration2024

Regional desynchronization of microglial activity is associated with cognitive decline in Alzheimer's disease.

Artem Zatcepin, Johannes Gnörich, Boris-Stephan Rauchmann, Laura M Bartos, Stephan Wagner, Nicolai Franzmeier, Maura Malpetti, Xianyuan Xiang, Yuan Shi, Samira Parhizkar and 34 more

Abstract read
In one paragraph

Article in Molecular neurodegeneration, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

44 authors.

Artem ZatcepinDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany. Artem.Zatcepin@med.uni-muenchen.de.ORCID 0000-0002-0224-088X
Johannes GnörichDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Boris-Stephan RauchmannInstitute of Neuroradiology, University Hospital LMU, Munich, Germany.
Laura M BartosDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Stephan WagnerDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Nicolai FranzmeierInstitute for Stroke and Dementia Research, University Hospital of Munich, LMU Munich, Munich, Germany.
Maura MalpettiDepartment of Clinical Neurosciences, Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, UK.
Xianyuan XiangBiomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, LMU Munich, Munich, Germany.
Yuan ShiGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Samira ParhizkarDepartment of Neurology, Washington University in St. Louis, St. Louis, MO, USA.
Maximilian GroschGerman Center for Vertigo and Balance Disorders, University Hospital of Munich, LMU Munich, Munich, Germany.
Karin Wind-MarkDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Sebastian T KunteDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Leonie BeyerDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Carolin MeyerGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Desirée BrösamleGerman Center for Neurodegenerative Disease (DZNE), Neuroimmunology and Neurodegenerative Diseases, Göttingen, Germany.
Ann-Christin WendelnGerman Center for Neurodegenerative Disease (DZNE), Neuroimmunology and Neurodegenerative Diseases, Göttingen, Germany.
Collins Osei-SarpongPlatform for Single Cell Genomics and Epigenomics (PRECISE), German Center for Neurodegenerative Diseasesand , University of Bonn and West German Genome Center, Bonn, Germany.
Steffanie HeindlInstitute for Stroke and Dementia Research, University Hospital of Munich, LMU Munich, Munich, Germany.
Arthur LieszInstitute for Stroke and Dementia Research, University Hospital of Munich, LMU Munich, Munich, Germany.
Sophia StoeckleinDepartment of Radiology, University Hospital, LMU Munich, Munich, Germany.
Gloria BiecheleDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Anika FinzeDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Florian EckenweberDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Simon LindnerDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Axel RomingerDepartment of Nuclear Medicine, Inselpital, Bern University Hospital, University of Bern, Bern, Switzerland.
Peter BartensteinDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Michael WillemBiomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, LMU Munich, Munich, Germany.
Sabina TahirovicGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Jochen HermsGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Katharina BuergerGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Mikael SimonsGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Christian HaassGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Rainer RupprechtDepartment of Psychiatry and Psychotherapy, University of Regensburg, Molecular Neurosciences, Regensburg, Germany.
Markus J RiemenschneiderDepartment of Neuropathology, Regensburg University Hospital, Regensburg, Germany.
Nathalie L AlbertDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Marc BeyerPlatform for Single Cell Genomics and Epigenomics (PRECISE), German Center for Neurodegenerative Diseasesand , University of Bonn and West German Genome Center, Bonn, Germany.
Jonas J NeherMunich Cluster for Systems Neurology (SyNergy), Munich, Germany.
Lars PaegerGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Johannes LevinGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Günter U HöglingerGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Robert PerneczkyGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Sibylle I ZieglerDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Matthias BrendelDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMicroglial activation is one hallmark of Alzheimer disease (AD) neuropathology but the impact of the regional interplay of microglia cells in the brain is poorly understood. We hypothesized that microglial activation is regionally synchronized in the healthy brain but experiences regional desynchronization with ongoing neurodegenerative disease. We addressed the existence of a microglia connectome and investigated microglial desynchronization as an AD biomarker.

methodsTo validate the concept, we performed microglia depletion in mice to test whether interregional correlation coefficients (ICCs) of 18 kDa translocator protein (TSPO)-PET change when microglia are cleared. Next, we evaluated the influence of dysfunctional microglia and AD pathophysiology on TSPO-PET ICCs in the mouse brain, followed by translation to a human AD-continuum dataset. We correlated a personalized microglia desynchronization index with cognitive performance. Finally, we performed single-cell radiotracing (scRadiotracing) in mice to ensure the microglial source of the measured desynchronization.

resultsMicroglia-depleted mice showed a strong ICC reduction in all brain compartments, indicating microglia-specific desynchronization. AD mouse models demonstrated significant reductions of microglial synchronicity, associated with increasing variability of cellular radiotracer uptake in pathologically altered brain regions. Humans within the AD-continuum indicated a stage-depended reduction of microglia synchronicity associated with cognitive decline. scRadiotracing in mice showed that the increased TSPO signal was attributed to microglia.

conclusionUsing TSPO-PET imaging of mice with depleted microglia and scRadiotracing in an amyloid model, we provide first evidence that a microglia connectome can be assessed in the mouse brain. Microglia synchronicity is closely associated with cognitive decline in AD and could serve as an independent personalized biomarker for disease progression.

Indexed as

Alzheimer DiseaseBrainCognitive DysfunctionMicrogliaAnimalsConnectomeDisease Models, AnimalFemaleHumansMaleMiceMice, TransgenicPositron-Emission TomographyReceptors, GABAReceptors, GABAAlzheimer’s diseaseBrain connectivityDementiaMicrogliaMicroglia desynchronizationMicroglia synchronicityNeuroinflammationPETTSPO

Identifiers

PMID39238030
PMCPMC11375924

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.